KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Taxes (2016 - 2025)

Jazz Pharmaceuticals has reported Change in Taxes over the past 14 years, most recently at -$34.8 million for Q4 2025.

  • Quarterly results put Change in Taxes at -$34.8 million for Q4 2025, changed 0.16% from a year ago — trailing twelve months through Dec 2025 was $37.2 million (up 352.5% YoY), and the annual figure for FY2025 was $37.2 million, up 352.5%.
  • Change in Taxes for Q4 2025 was -$34.8 million at Jazz Pharmaceuticals, down from $12.7 million in the prior quarter.
  • Over the last five years, Change in Taxes for JAZZ hit a ceiling of $46.3 million in Q2 2025 and a floor of -$46.5 million in Q2 2021.
  • Median Change in Taxes over the past 5 years was $8.5 million (2022), compared with a mean of $1.5 million.
  • Biggest five-year swings in Change in Taxes: crashed 2264.41% in 2023 and later surged 1359.08% in 2025.
  • Jazz Pharmaceuticals' Change in Taxes stood at -$24.7 million in 2021, then soared by 93.84% to -$1.5 million in 2022, then crashed by 2264.41% to -$35.9 million in 2023, then increased by 3.06% to -$34.8 million in 2024, then grew by 0.16% to -$34.8 million in 2025.
  • The last three reported values for Change in Taxes were -$34.8 million (Q4 2025), $12.7 million (Q3 2025), and $46.3 million (Q2 2025) per Business Quant data.